Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ: CNSP )

0.1080 -0.0020 (-1.82%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,805,877
Open 0.1050
Bid (Size) 0.1082 (157)
Ask (Size) 0.1124 (1)
Prev. Close 0.1100
Today's Range 0.1008 - 0.1200
52wk Range 0.0955 - 70.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Research Shows Brain Tumors Grow by Hijacking Circadian Clocks
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11
Via Investor Brand Network

Performance

YTD
-99.82%
-99.82%
1 Month
-16.92%
-16.92%
3 Month
-22.86%
-22.86%
6 Month
-95.16%
-95.16%
1 Year
-99.82%
-99.82%

More News

Read More
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
Via ACCESSWIRE
AI Model Promises New Way to Detect Brain Malignancies
Via Investor Brand Network
Topics Artificial Intelligence Death
Exposures Artificial Intelligence Death
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Progress in Pivotal Study of Berubicin for Glioblastoma Treatment
Via Investor Brand Network
Exposures Product Safety
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
New Graphene Chip Could Revolutionize Brain Cancer Treatment
Via Investor Brand Network
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
Via ACCESSWIRE
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Via ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting
Via Investor Brand Network
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances Glioblastoma Treatment with Berubicin Amid Strong Financial Position
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Berubicin’s Potential in Glioblastoma Treatment During KOL Connect Event
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Granted Nasdaq Extension for Compliance
Via Investor Brand Network
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Via ACCESSWIRE
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG
Via AB Newswire
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures $3 Million in Registered Direct Offering
Via Investor Brand Network
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Nasdaq Down 2%; US Crude Stocks Increase
Via Benzinga
Gold Moves Lower; AT&T Earnings Top Views
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Why CNS Pharmaceuticals (CNSP) Stock Is Up 86%
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.